The merger with Vertex is a clear premium event for CRNX holders. Monitor for the definitive proxy statement and stockholder vote date. The deal is subject to regulatory and stockholder approvals; any delays or competing bids could create volatility. Given the low historical T+20 win rate on CRNX reports, traders should focus on the binary outcome of the vote rather than short-term price action.
Price Chart
Executive Summary
Crinetics Pharmaceuticals filed this DEFA14A as soliciting material in connection with its pending merger with Vertex Pharmaceuticals, announced July 6, 2026. The filing discloses non-compete agreements with key executives (CEO, CFO, CSO, CCO) and cash payments totaling $200,000 to three of them. The merger is a transformative event for CRNX shareholders, who will vote on the deal at a future stockholder meeting.
Key Facts
- Merger Agreement with Vertex Pharmaceuticals dated July 6, 2026, under which Crinetics will become a wholly owned subsidiary of Vertex.
- Non-compete agreements entered into with CEO R. Scott Struthers, CFO Tobin Schilke, CSO Stephen Betz, and CCO Isabel Kalofonos, effective for one year post-close.
- Cash consideration for non-compete agreements: $140,000 to Schilke, $30,000 each to Betz and Kalofonos.
- Stockholder meeting to be announced to vote on the merger; definitive proxy statement to be filed.
Financial Impact
Merger consideration not disclosed in this filing; non-compete cash payments total $200,000.
Risk Factors
- Failure to obtain stockholder approval for the merger.
- Regulatory hurdles or antitrust review could delay or block the transaction.
- Termination of the Merger Agreement under certain conditions, including a termination fee.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-028209 |
| Document: 0001140361-26-028209-index-headers.html | 0001140361-26-028209 |
| Document: 0001140361-26-028209-index.html | 0001140361-26-028209 |
| Document: 0001140361-26-028209.txt | 0001140361-26-028209 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access